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ABSTRACT
Effects of race or ethnicity on survival after high-dose chemoradiation followed by stem cell transplantation (SCT)
have not been thoroughly evaluated.We analyzed survival according to racial/ethnic categories for 3587 consecutive
patients who had SCT at a single US institution between July 1992 and December 2000. Among 1366 patients who
received autologous SCT, race or ethnicity was not significantly associated with survival. In contrast, among 2221
patients who received allogeneic SCT from HLA-matched unrelated or sibling donors, blacks had a significantly
greater mortality than whites (unadjusted hazard ratio, 1.65; 95% confidence interval, 1.21-2.25). Mortality among
other racial or ethnic groups was not significantly different from that among whites. The greater mortality hazard
among blacks persisted after controlling for donor type, pretransplantation risk category, patient age, donor/patient
sex, and cytomegalovirus exposure (hazard ratio, 1.71; 95% confidence interval, 1.25-2.34). SCT from both
HLA-matched unrelated andHLA-identical sibling donors was associated withmore severe acute graft-versus-host
disease and higher nonrelapse mortality among blacks compared with whites. Furthermore, blacks who received
SCT for chronicmyeloid leukemia had longer diagnosis-to-transplantation intervals thanwhites. Amatched-cohort
analysis showed that the higher mortality among blacks could not be explained by obvious socioeconomic differ-
ences. The higher incidence of severe graft-versus-host disease among blacks compared with whites, both with
HLA-identical sibling donors, might be related to yet-unidentified “immune-enhancing” genetic polymorphisms.
We cannot exclude the possibility that the increasedmortality risk among blacks after discharge from the transplant
center might in part be related to unidentified sociocultural differences that influence medical care.
© 2005 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
In the United States, poorer survival for blacks
ompared with whites has been reported after a diag-
osis of cancer [1-4]. Reasons for this disparity are
omplex and may include racial differences in cancer
iology [5,6], pharmacogenetics [7,8], and the spec-
rum of comorbid conditions [1]. In addition, the
uccess of cancer treatments can be affected by socio-
conomic and cultural factors, which may inﬂuence
ccess to and use of medical care [3,4].
Allogeneic hematopoietic stem cell transplantation
SCT) after myeloablative chemoradiation is a potentially
urative treatment for patients with hematologic malignan- c
B&MTies. In keeping with the results of cancer treatments using
onventional chemotherapy or radiation therapy, mortality
fter high-dose conditioning and allogeneic SCT seems
reater in patients who belong to certain racial or ethnic
roups. After allogeneic SCT from unrelated donors, for
xample, blacks have a worse survival than whites, in part
ecause of the difﬁculty in ﬁnding unrelated donors
atched for HLAs [9-11]. As a result, a greater proportion
f blacks than whites receive HLA-mismatched transplants
rom unrelated donors, and this may cause more graft-
ersus-host disease (GVHD), with its associated morbidity
nd mortality. Blacks may have lower survival than whites
ven after HLA-identical sibling SCT, although deﬁnitive
onclusions are limited by small sample sizes [12].
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2Among recipients of renal allografts from HLA-
dentical living-related donors, blacks have a signiﬁcantly
horter median graft survival than whites [13,14]. This
ould be interpreted to suggest that genetic polymor-
hisms associated with an enhanced immune response
gainst the graft might be more prevalent among blacks
han among whites [15-17]. In addition, socioeconomic
isparities between blacks and whites could affect med-
cal care and graft survival.
The extent to which socioeconomic disparities
etween different racial or ethnic groups might affect
urvival after allogeneic SCT is poorly understood.
n theory, socioeconomic factors may inﬂuence
hether SCT is available to medically eligible pa-
ients, whether patients are referred for transplanta-
ion in a timely fashion, and whether adequate medical
are is provided and used after discharge from the
ransplant center. Quality medical care after alloge-
eic SCT seems to be of particular importance, be-
ause morbidity and mortality associated with GVHD
nd delayed immune reconstitution may occur months
o years after transplantation. Therefore, biological
omplications such as GVHD and infections have to
e interpreted in the context of their socioeconomic
nd cultural backgrounds, which may inﬂuence the
ecognition and treatment of these complications.
his retrospective study was conducted to assess race/
thnicity-speciﬁc survival after SCT for hematologic
iseases and to identify possible reasons for any dif-
erences.
ATERIALS AND METHODS
This retrospective cohort study included all patients
dentiﬁed with malignant and nonmalignant hemato-
ogic diseases who had myeloablative autologous or al-
ogeneic SCT from HLA-matched sibling or unrelated
onors at the Fred Hutchinson Cancer Research Center
FHCRC) or the afﬁliated Seattle Veterans Administra-
ion Puget Sound Health Care Center between July
992 and December 2000 (n  3587). All patients gave
nformed consent in writing with forms approved by the
nstitutional Review Board of the FHCRC. Racial or
thnic identiﬁcation was categorized as white, black,
ispanic, Asian, Native American, or “other,” according
o self-report.
LA Matching, Preparative Regimens, and
rophylaxis against GVHD and Infections
HLA types of donors and recipients were deter-
ined by serologic and DNA-based methods. Unrelated
onors were selected to minimize HLA disparity with
ecipients as much as possible. The preparative regimens
re categorized in Table 1. Most allogeneic recipients
ere given cyclosporine plus methotrexate after the
ransplantation for prophylaxis against GVHD [18]. u
32ome patients received cyclosporine plus methylpred-
isolone [19] or trimetrexate [20], tacrolimus plus meth-
trexate [21], or methotrexate alone [22]. Prophylactic
edications against infections were administered as de-
cribed previously [23-25].
retransplantation Risk Categories
Hematologic diseases were categorized according
o their associated risks of posttransplantation relapse
nd nonrelapse mortality. Chronic myeloid leukemia
CML) in chronic phase was deﬁned as low risk, CML
n blast phase and any hematologic malignancy in
elapse was deﬁned as high risk, and all others were
eﬁned as intermediate risk.
ocioeconomic Indicators
All black patients who had received allografts be-
ween July 1992 and December 2000 (n  55) were
dentiﬁed and matched with white controls in a 1:2
atio. Pairs were matched for age, pretransplantation
isk category, transplantation year, donor type, and
ytomegalovirus exposure. Information regarding pa-
ient education, employment, household income, and
edicaid or Social Security income eligibility at the
ime of transplantation was extracted from social work
ecords. In cases for which documentation of educa-
ion or household income was not available, these
ndicators were categorized through consideration of
ccupation and employment, which were recorded
onsistently.
tatistical Analysis
Proportional hazards regression models were used
o assess the association of race with failure for time-
o-event end points. A base model was ﬁt with vari-
bles previously known or suspected to be associated
ith the appropriate failure type. Once this base
odel was determined, race or ethnicity was added to
he model to estimate its association with outcome
fter controlling for nonrace factors. Only variables
hat were statistically signiﬁcantly (P  .05) or sug-
estively (.05  P  .10) associated with outcome
ere included in the base model. Variables that were
ot included in the base model were tested later to
etermine whether their inclusion would affect the
ssociation between race or ethnicity and the hazard
f mortality: a change in the hazard ratio (HR) of
20% was considered to be large enough to warrant
nclusion of the variable examined. Regression models
or the matched-cohort analyses did not include any
onsocioeconomic variables, because all of these fac-
ors were used for matching. From the list of white
atients who were considered adequate matches, 2
ere randomly selected for each black patient. Unad-
usted estimates of overall survival were obtained by
sing the method of Kaplan and Meier. Two-sided P
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Ethnicity and Survival after SCT
Balues resulting from regression models were esti-
ated from the Wald test, and no adjustments were
ade for multiple comparisons.
ESULTS
atient Characteristics
The study population of 3587 patients comprised
925 whites, 142 Hispanics, 92 blacks, 68 Asians, 45
ative Americans, and 93 individuals who listed other
acial or ethnic categories (4 East Indian, 11 Middle
able 1. Characteristics of Patients with Allogeneic Transplants
Variable
White
(n  1865)
edian patient age, y (range) 39.8 (1-69)
edian donor age, y (range) 39.2 (1-72)
ransplant year, n (%)
1992-1995 810 (43)
1996-2000 1055 (57)
onor/patient sex, n (%)
Female 3 male 427 (23)
Other combination 1438 (77)
onor/patient CMV exposure, n (%)
/ 444 (24)
/ 471 (25)
/ 266 (14)
/ 678 (36)
Missing data 6 (<1)
iagnosis, n (%)
Aplastic anemia 50 (3)
Acute lymphocytic leukemia 219 (12)
Acute myeloid leukemia 422 (23)
Chronic lymphocytic leukemia 24 (1)
Chronic myeloid leukemia 649 (35)
Myelodysplastic syndrome 248 (13)
Hodgkin lymphoma 28 (2)
Non-Hodgkin lymphoma 100 (5)
Multiple myeloma 71 (4)
Other 54 (3)
retransplantation risk category, n (%)
Low 482 (26)
Intermediate 894 (48)
High 489 (26)
onor type, n (%)
HLA-identical sibling 935 (50)
Unrelated volunteer 930 (50)
tem cell source, n (%)
Bone marrow 1533 (82)
G-PBMC 306 (16)
Bone marrow  G-PBMC 4 (<1)
Cord blood 22 (1)
reparative regimen, n (%)
TBI-containing, <1200 cGy 453 (24)
TBI-containing, >1200 cGy 681 (37)
Busulfan/cyclophosphamide 416 (22)
Other 315 (17)
VHD prophylaxis, n (%)
Cyclosporine/methotrexate 1518 (81)
Other 347 (19)
MV indicates cytomegalovirus; G-PBMC, granulocyte colony-stim
body irradiation; GVHD, graft-versus-host disease.astern, 20 Jewish, and 58 multiple categories). Racial c
B&MTnd ethnic categories were unknown for 222 patients.
able 1 shows selected demographic and baseline
haracteristics for the allogeneic group.
urvival after SCT
No statistically signiﬁcant differences in overall
urvival were detectable after autologous SCT among
he different racial or ethnic groups (P  .55; adjusted
lobal likelihood ratio test; Figure 1A). After alloge-
eic SCT, blacks had a signiﬁcantly higher mortality
isk compared with whites (unadjusted HR, 1.65; 95%
ck
55)
Asian
(n  51)
Hispanic
(n  112)
Native
American
(n  26)
1-59) 40.6 (2-60) 34.3 (1-57) 37.4 (10-56)
10-69) 38.8 (8-62) 33.4 (1-64) 37.9 (18-63)
47) 11 (22) 41 (37) 8 (31)
53) 40 (78) 71 (63) 18 (69)
38) 20 (39) 32 (29) 5 (19)
62) 31 (61) 80 (71) 21 (81)
47) 31 (61) 57 (51) 14 (54)
20) 9 (18) 15 (13) 4 (15)
18) 3 (6) 16 (14) 0
15) 6 (12) 23 (21) 8 (31)
1 (2) 1 (1) 0
2) 1 (2) 9 (8) 2 (8)
9) 7 (14) 24 (21) 4 (15)
15) 13 (25) 23 (21) 9 (35)
2) 0 0 0
55) 21 (41) 41 (37) 7 (27)
7) 7 (14) 10 (9) 1 (4)
0 0 0
5) 0 0 1 (4)
4) 1 (2) 2 (2) 1 (4)
1) 1 (2) 3 (3) 1 (4)
25) 18 (35) 30 (27) 2 (8)
47) 26 (51) 58 (52) 17 (65)
27) 7 (14) 24 (21) 7 (27)
55) 29 (57) 61 (54) 17 (65)
45) 22 (43) 51 (46) 9 (35)
87) 40 (78) 94 (84) 19 (73)
9) 11 (22) 17 (15) 7 (27)
0 0 0
4) 0 1 (1) 0
16) 6 (12) 25 (22) 5 (19)
36) 19 (37) 50 (45) 11 (42)
20) 19 (37) 25 (22) 6 (23)
27) 7 (14) 12 (11) 4 (15)
87) 46 (90) 89 (79) 24 (92)
13) 5 (10) 23 (21) 2 (8)
g factor–mobilized peripheral blood mononuclear cells; TBI, totalBla
(n 
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ulatinonﬁdence interval [CI], 1.21-2.25), and Asians had a
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2ower mortality risk compared with whites (unadjusted
R, 0.62; 95% CI, 0.39-0.97; Figure 1B). After ad-
usting for donor type, pretransplantation risk cate-
ory, patient age, donor/patient sex, and cytomegalo-
irus exposure, the difference in mortality between
lacks and whites remained statistically signiﬁcant
HR, 1.71; 95% CI, 1.25-2.34; Table 2). Also, limiting
his analysis to patients with leukemia (acute myeloid
eukemia, acute lymphoblastic leukemia, and CML)
nd myelodysplastic syndrome produced similar re-
igure 1. Kaplan-Meier estimates of survival of patients after he
utologous transplantations. B, Allogeneic transplantations. C, Unre
6.8 months among all surviving white patients (n  842) and 70.8
able 2. Hazard of Overall Mortality after Allogeneic Stem Cell Tran
Variable n HR
hite 1865 1.0
lack 55 1.65
sian 51 0.62
ispanic 112 0.98
ative American 26 0.92
R indicates hazard ratio; CI, conﬁdence interval.
Adjusted for donor type, pretransplantation risk category, patienMaterials and Methods.
34ults (HR, 1.61; 95% CI, 1.13-2.28). The adjusted
ortality hazards among the other racial and ethnic
roups were not signiﬁcantly different from the mor-
ality hazard among whites. Therefore, subsequent
nalyses focused on black and white patients.
LA Compatibility between Unrelated Donors
nd Recipients
Thirty percent of blacks and 9% of whites were
ismatched with their donors for HLA-A antigens.
ietic stem cell transplantation according to race or ethnicity. A,
onors. D, HLA-identical sibling donors. The median follow-up was
hs among all surviving black patients (n  14).
ion, According to Race and Ethnicity
justed Adjusted*
95% CI HR 95% CI
— 1.0 —
1.21-2.25 1.71 1.25-2.34
0.39-0.97 0.70 0.45-1.11
0.76-1.27 1.09 0.84-1.42
0.54-1.56 0.87 0.51-1.47
patient/donor sex, and cytomegalovirus exposure as described inmatopo
lated dsplantat
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Ethnicity and Survival after SCT
Bwenty-six percent of blacks and 5% of whites were
ismatched for HLA-B antigens. Thirteen percent of
lacks and 11% of whites were mismatched for HLA-
RB1 alleles. Sixty-one percent of blacks and 22% of
hites were mismatched at a single HLA locus, and
% of blacks and 1% of whites were mismatched at 2
r more loci.
nfluence of Donor Type on Mortality
Blacks had lower survival than whites after SCT
rom both unrelated donors and HLA-identical
iblings (Figure 1, C and D). After adjusting for pa-
ient age, pretransplantation risk category, patient/
onor sex, and cytomegalovirus exposure, the hazard
f mortality after transplantation from unrelated do-
ors and HLA-identical sibling donors remained sta-
istically signiﬁcantly greater among blacks than
mong whites. After further adjustment for the degree
able 3. Hazard of Overall Mortality, Nonrelapse Mortality, and Rela
llogeneic Stem Cell Transplantation According to Donor Type
Donor Type
Black
(n)
White
(n)
Over
H
ll*† 55 1865 1.71
LA-identical sibling* 30 935 1.79
nrelated volunteer
Model 1* 25 930 1.62
Model 2*‡ 1.46
R indicates hazard ratio; CI, conﬁdence interval.
Adjusted for pretransplantation risk category, patient age, patient
Methods.
Additionally adjusted for donor type.
Additionally adjusted for the number of mismatched HLA-A and
able 4. Distribution of Socioeconomic Indicators among Black and Wh
Variable
ducation, n (%)
High school only
Some college
College completed
Information not available
nnual household income, n (%)
<$20 000
$20 000-$50 000
>$50 000
Information not available
mployment before transplantation, n (%)
Unemployed
Part-time
Full-time
Information not available
edicaid or Social Security Income eligibility, n (%)
Yes
No
Information not available
All black patients who had received allogeneic stem cell transplants
white controls in a 1:2 ratio. Pairs were matched for age,
cytomegalovirus exposure. Percentages were calculated on the bChi-square test among patients with data available.
B&MTf HLA mismatching among recipients of unrelated
rafts, this difference was no longer statistically sig-
iﬁcant (Table 3).
ocioeconomic Indicators and Mortality
A matched-cohort analysis was performed to as-
ess whether the greater mortality among blacks com-
ared with whites might be related to socioeconomic
ifferences that could have inﬂuenced posttransplan-
ation care. The distribution of socioeconomic indi-
ators among blacks (n  55) and whites (n  110)
atched for age, transplantation year, donor type,
retransplantation risk category, and cytomegalovirus
xposure is shown in Table 4. There were no striking
ifferences between blacks and whites for the catego-
ies evaluated. Compared with whites, black patients
ad slightly less formal education and lower house-
old incomes; also, blacks were slightly less likely to
tality among Black Patients Compared with White Patients after
rtality,
CI)
Nonrelapse Mortality,
HR (95% CI)
Relapse Mortality,
HR (95% CI)
2.35) 1.74 (1.20-2.54) 2.03 (1.12-3.65)
2.80) 1.86 (1.08-3.21) 1.97 (0.91-4.28)
2.54) 1.66 (0.98-2.79) 1.96 (0.79-4.85)
2.53) 1.42 (0.82-2.46) 1.96 (0.79-4.86)
sex, and cytomegalovirus exposure, as described in Materials and
igens and HLA-DR alleles.
ents*
(n  55) White (n  110) P Value†
(37) 38 (36) .08
(43) 29 (28)
(20) 38 (36)
6 5
(55) 46 (44) .22
(38) 43 (41)
(6) 16 (15)
8 5
(45) 48 (46) .60
(25) 20 (19)
(29) 37 (35)
4 5
(45) 39 (37) .38
(55) 66 (63)
8 5
n July 1992 and December 2000 were identiﬁed and matched with
ntation year, donor type, pretransplantation risk category, and
proportions of patients for whom information was available.pse Mor
all Mo
R (95%
(1.25-
(1.15-
(1.03-
(0.92-
/donorite Pati
Black
18
21
10
26
18
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13
15
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2e employed full-time and depended more on Med-
caid or Social Security Income for health insurance
overage. None of these differences, however, was
tatistically signiﬁcant (Table 4).
In this matched-cohort analysis, the unadjusted
azard of overall mortality was signiﬁcantly greater
mong blacks than among whites (HR, 1.79; 95% CI,
.19-2.68). After adjusting for socioeconomic indica-
ors, the HR was not substantially different from the
nadjusted HR (HR, 1.77; 95% CI, 1.12-2.80). Ad-
ustment for various combinations of socioeconomic
ndicators produced comparable results (data not
hown).
ause-Specific Mortality among Blacks Compared
ith Whites
We categorized deaths as occurring with recurrent
alignancy (relapse mortality) or without recurrent ma-
ignancy (nonrelapse mortality). The adjusted hazards of
oth relapse mortality and nonrelapse mortality after
llogeneic transplantation were statistically signiﬁcantly
reater among blacks than among whites (Table 3).
mong the subgroup of patients who had SCT from
LA-identical siblings, the adjusted hazard of nonre-
apse mortality was statistically signiﬁcantly greater
mong blacks than among whites, whereas the adjusted
azard of relapse mortality was suggestively greater
mong blacks than among whites. Among patients who
ad SCT from unrelated donors, the adjusted hazards of
elapse mortality and nonrelapse mortality were sugges-
ively greater among blacks compared with whites.
VHD and Recurrent Malignancy
Among recipients with HLA-identical sibling do-
ors, 11 (37%) of 30 blacks and 183 (21%) of 855
hites developed severe (grades III/IV) acute GVHD
unadjusted P  .047). Among recipients with unre-
ated donors, 14 (61%) of 23 blacks and 317 (36%) of
able 5. Disease Phases at the Time of Allogeneic Stem Cell Transplan
atients with Chronic Myeloid Leukemia (CML)
Variable
CML Ph
Black, n (%)
LA-identical sibling transplantations
All Patients 14
Chronic phase 9 (64)
Accelerated phase/blast phase in
remission 4 (29)
Blast phase 1 (7)
nrelated donor transplantations
All patients 15
Chronic phase 4 (27)
Accelerated phase/blast phase in
remission 9 (60)
Blast phase 2 (13)ne black patient and 9 white patients with missing diagnosis-to-transpla
3684 whites developed severe acute GVHD (unad-
usted P  .014). These results were unaltered after
djusting for various factors in multivariate logistic
egression models (data not shown). Extensive chronic
VHD occurred among 40% of blacks and 37% of
hites with HLA-identical sibling donors (unadjusted
 .73) and among 32% of blacks and 43% of whites
ith unrelated donors (unadjusted P  .43). The haz-
rd of recurrent malignancy was suggestively greater
mong blacks than among whites (HR, 1.61; 95% CI,
.95-2.73). Although Asians had a superior survival
ompared with whites in the unadjusted analysis (Ta-
le 2), rates of acute and chronic GVHD and relapse
ere not statistically signiﬁcantly different between
he 2 groups.
Early” and “Late” Mortality after Transplantation
During the ﬁrst 100 days after transplantation,
atients received their medical care at the FHCRC
efore returning to their referring physicians. The
ncreased mortality among blacks compared with
hites occurred predominantly after day 100 (HLA-
dentical sibling donors: HR, 2.32; 95% CI, 1.34-4.04;
nrelated donors: HR, 1.98; 95% CI, 1.05-3.75). Dif-
erences before day 100 were less striking and were
ot statistically signiﬁcant (HLA-identical sibling do-
ors: HR, 1.46; 95% CI, 0.58-3.68; unrelated donors:
R, 1.59, 95% CI, 0.67-3.77).
ML Stage at the Time of SCT and Time from
iagnosis to Transplantation
CML was the most frequent indication for allogeneic
CT. CML phase at the time of SCT and diagnosis-
o-transplantation intervals both inﬂuence survival af-
er SCT [26,27]. Among CML patients with HLA-
dentical sibling donors, only 64% of blacks were in
hronic phase at the time of the transplantation, com-
ared with 82% of whites. Among CML patients with
nd Diagnosis-To-Transplantation Intervals among Black and White
ransplantation
Median Years from Diagnosis
to Transplantation
White, n (%) Black White
241 0.89 0.44
198 (82) 0.73 0.44
33 (14) 2.25 0.46
10 (4) 1.84 0.53
399 2.97 1.07
282 (71) 1.96 0.96
93 (23) 3.40 1.61
24 (6) 1.17/8.64 1.08tation a
ase at Tntation information or juvenile CML are not included.
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Ethnicity and Survival after SCT
Bnrelated donors, only 27% of blacks were in chronic
hase, compared with 71% of whites (Table 5).
mong recipients with HLA-identical sibling donors,
edian diagnosis-to-transplantation intervals were
.89 years (range, 0.27-21.27 years) among blacks and
.44 years (range, 0.15-7.70 years) among whites.
ith unrelated donors, the median intervals were
.97 years (range, 0.48-8.64 years) among blacks and
.07 years (range, 0.07-27.41 years) among whites.
mong all patients with CML, the mortality hazard
as greater among blacks compared with whites after
djusting for donor type, pretransplantation risk cat-
gory, patient age, patient/donor sex, and cytomega-
ovirus exposure (HR, 2.03; 95% CI, 1.26-3.29). After
urther adjusting for time from diagnosis to transplan-
ation, the HR decreased to 1.83 (95% CI, 1.11-3.02).
ISCUSSION
Our results show that overall survival after allogeneic
CT was signiﬁcantly worse among blacks than among
hites and other minority groups. In contrast, survival
fter autologous SCT was comparable among all groups
xamined. The worse survival among blacks compared
ith whites after allogeneic SCT was in part related to
ecurrent malignancy and more severe GVHD.
Analysis among CML patients showed that the
ime intervals from diagnosis to transplantation were
ore than twice as long among blacks compared with
hites, and this suggests that blacks may have had
ore advanced disease at the time of SCT. Differ-
nces between blacks and whites in time intervals from
iagnosis to transplantation were greater not only
mong patients with unrelated donors, but also among
atients with HLA-identical sibling donors. There-
ore, the greater difﬁculty in ﬁnding suitably matched
nrelated donors does not fully explain the delay of
CT among blacks. Delayed referral and resistance to
eferral to a transplant center might also lengthen the
ime interval from diagnosis to transplantation. How-
ver, controlling for the time interval from diagnosis
o transplantation did not fully account for the greater
ortality hazard among blacks compared with whites.
t is therefore possible that the diagnosis was made
ater in the course of the disease in blacks compared
ith whites.
We hypothesized that the difference in survival
etween blacks and whites might be linked to eco-
omic hardship, which could impede compliance with
omplex and expensive drug regimens that have to be
iven over prolonged periods after transplantation.
fter renal transplantation, for example, socioeco-
omic status and failure to adhere to immunosuppres-
ive regimens have been closely linked to graft loss,
specially among black patients [28]. Contrary to our
ypothesis, we did not ﬁnd an association between t
B&MTconomic hardship and survival in our study, perhaps
ecause differences in socioeconomic indicators be-
ween blacks and whites in our study population were
ot as pronounced as in other studies [2]. Moreover,
he differences in mortality between blacks and whites
hat occurred predominantly after day 100 were not
ubstantially reduced after adjusting for education,
ncome, employment, and insurance coverage. Socio-
ultural factors unaccounted for in our analysis could
e associated with differences in medical care received
y blacks and whites after discharge from the trans-
lant center.
Our results suggest that much of the increased
ortality after allogeneic SCT among blacks is related
o GVHD. The higher risk of severe acute GVHD
mong blacks after unrelated SCT is at least partly
ttributable to the difﬁculty of ﬁnding suitable donors
9-11]. According to data reported by the National
arrow Donor Program in 1999, the likelihood of
nding an HLA-A, -B, and -DR serologically matched
nrelated donor was 80% for whites and only 30% for
lacks. This difference has been attributed to both a
maller donor pool and a greater degree of HLA
olymorphisms with relatively large numbers of HLA
aplotypes speciﬁc to blacks [9,10].
Among patients with HLA-identical sibling do-
ors, the higher rate of severe acute GVHD among
lacks compared with whites (37% versus 21%) was
nexpected, because donors and recipients were geno-
ypically matched for HLA class I and class II alleles.
ertain drugs used for prophylaxis against GVHD
ould be less protective in blacks than in whites. For
xample, a methylenetetrahydrofolate reductase poly-
orphism (C677T) that could increase the suscepti-
ility of donor T cells to the antimetabolic effects of
ethotrexate [29] was found less frequently among
lacks than among whites [7,30]. The higher risk of
VHD in blacks could reﬂect the evolutionary sur-
ival advantage of strong immune responses in popu-
ations under selection by the greater challenge of
nfections in tropical climates as compared with tem-
erate climates. Such pathogen-driven selection has
een invoked to explain the higher diversity of HLA-B
ntigens among Indians in South and Central America
s compared with those in North America [31-33].
he distribution of polymorphisms in genes that reg-
late the immune response is greatly inﬂuenced by
thnicity [16,17,34], and some of these polymor-
hisms have been associated with increased or de-
reased risks of GVHD and mortality after SCT [35].
he ﬁnding that GVHD is a relatively infrequent
omplication after HLA-identical sibling SCT for
ickle cell disease [36], a nonmalignant disorder that
redominantly affects blacks in the United States,
ight be explained by the substantially younger age
nd the absence of exposure to cytotoxic therapy in
his pediatric patient population.
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2The International Bone Marrow Transplant Reg-
stry (IBMTR) recently reported an increased hazard
f mortality among Hispanics compared with whites
ho had SCT from HLA-identical siblings in the
nited States and Canada [37]. The increased risk of
ortality among Hispanics was detectable among pa-
ients who had transplantations from 1995 to 1999,
ut not among those who had transplantations from
990 to 1994. The results also showed a consistent
rend indicating a 20% to 30% increased risk of mor-
ality among blacks compared with whites during each
f the 3 time periods evaluated (1985-1989, 1990-
994, and 1995-1999). Although this trend for each
eriod did not reach statistical signiﬁcance, the con-
istency of results was striking, and a comparison
cross all 3 periods would likely have led to the con-
lusion that the risk of mortality was higher among
lacks than among whites, as shown by our study. We
id not ﬁnd differences in mortality rates between
ispanics and whites, and the survival disadvantage
mong blacks compared with whites was more pro-
ounced in our study than in the IBMTR study. The
maller number of racial and ethnic minority patients
imited our analysis and did not allow subcategoriza-
ion according to different time periods. However, a
igher uniformity of treatment protocols and proce-
ures might have made it easier to detect differences
n outcomes between blacks and whites in our study
han in the IBMTR study.
In a second recent publication by the IBMTR, [38]
nvestigators reported an increased risk of acute
VHD among white, black, and Irish patients com-
ared with Japanese and Scandinavian patients after
one marrow transplantation from HLA-identical sib-
ings. Although the risks of acute GVHD (grades
I-IV) were not signiﬁcantly different between whites
nd blacks in this IBMTR study, the hazard of non-
elapse mortality among blacks was 2-fold higher than
mong whites. These ﬁndings are in keeping with our
esults, which showed that the increased risk of acute
VHD among blacks compared with whites who re-
eived transplants from related donors pertained only
o severe (grades III-IV) acute GVHD. Also, only
9% of Asians included in our studies were Japanese,
nd this might have obscured the potential association
etween Japanese race and acute GVHD or nonre-
apse mortality.
In conclusion, after allogeneic SCT from HLA-
dentical sibling donors, the hazard of mortality was
reater among blacks than among whites and other
acial or ethnic groups. This unexpected ﬁnding was
argely attributable to more frequent severe GVHD
mong blacks compared with whites that might be
xplained in part by more vigorous immune responses
mong blacks. Given that the increased mortality
mong blacks occurred predominantly after discharge
rom the transplant center, a contribution of uniden- 1
38iﬁed socioeconomic or cultural factors that might
ffect access to or delivery of medical care in the home
nvironment cannot be excluded. The limitations of
ur study included the relatively small number of
atients belonging to racial and ethnic minority
roups and the heterogeneity of the population with
egard to underlying diagnoses. Restricting the anal-
sis to the relatively large subgroup of patients with
he uniform diagnosis of CML, however, did not pro-
uce different results. Nevertheless, unraveling the
etwork of genetic polymorphisms that inﬂuence the
mmune response could help to explain racial differ-
nces in rejection rates after solid organ transplanta-
ion and GVHD after SCT.
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Erratum
The Abstracts Supplement to the February 2005 issue of BBMT included an abstract (No. 160, “Cross-
reactivity of Epstein Barr Virus-Specific Cytotoxic T Lymphocytes with an HLA-C Locus Allele”), sub-
mitted by Carolyn Keever-Taylor. This abstract has been withdrawn since the supplement went to press.239
